Renaissance Capital logo

Editing your genes: Editas Medicine sets terms for $100 million IPO

January 25, 2016
Editas Medicine logo

Editas Medicine, which is developing gene editing therapies based on CRISPR technology, announced terms for its IPO on Monday.

The Cambridge, MA-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Editas Medicine would command a fully diluted market value of $625 million.

Editas Medicine was founded in 2013 and booked $1 million in sales for the 12 months ended September 30, 2015. It plans to list on the Nasdaq under the symbol EDIT. Morgan Stanley, J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of February 1, 2016.